Ferric-carboxymaltose Hypophosphataemia: case reportIn a study of 400 patients, who received ferric-carboxymaltose between January 2017 and September 2019, a patient [age and sex not stated] was described, who developed hypophosphataemia during treatment with ferric-carboxymaltose. The patient had been receiving IV ferric-carboxymaltose [Ferinject; dosage and indication not stated]. However, after treatment, the patient developed severe hypophosphataemia associated with ferric-carboxymaltose [duration of treatment to reaction onset and outcome not stated].Cianci N, et al. No acute clinically-significant events due to hypophosphataemia post-ferric carboxymaltose therapy: An audit. Gut 70 (Suppl. 1): A166-A167 (plus poster) abstr. P241, 2021.